Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer

NCT03412877 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03412877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03412877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
September 6, 2018
Completion date
March 23, 2029
Enrollment
285 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, endocrine tumors, gastrointestinal/genitourinary cancers, multiple myeloma, neuroendocrine tumors, non-small cell lung cancer, ovarian cancer